EUVIMEDEUVIMED entdecken
Klinische Studie (Phase IV)VergleichsstudieMultizentrische StudieRandomisierte kontrollierte StudieOpen Access

Sex Differences in Transcatheter Aortic Valve Implantation Outcomes in Patients on Oral Anticoagulants: A Popular PAUSE TAVI SubAnalysis

Kees H van Bergeijk iD, Daniël C Overduin, Constantijn S Venema iD, Dirk Jan van Ginkel, Hindrik W van der Werf iD, Ad F M van den Heuvel iD, Adriaan A Voors iD, Joanna J Wykrzykowska iD, Jurrien M Ten Berg iD

Journal of the American Heart Association · 2025

DOI: 10.1161/jaha.125.043448 ↗

Kurz gefasst

Klinische Studie (Phase IV) in der Zeitschrift Journal of the American Heart Association, 2025. Verfasst von Kees H van Bergeijk und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology University of Groningen, University Medical Center Groningen the Netherlands. Hauptthemen laut MEDLINE: Anticoagulants, Aortic Valve Stenosis, Stroke, Transcatheter Aortic Valve Replacement. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Many patients undergoing transcatheter aortic valve implantation (TAVI) have an indication for oral anticoagulation (OAC). Our aim was to study sex differences in outcomes after TAVI, depending on the type and regimen of vitamin K antagonist versus direct OAC.

Methods

The Popular PAUSE TAVI (Periprocedural Continuation Versus Interruption of Oral Anticoagulant Drugs During Transcatheter Aortic Valve Implantation) was a randomized clinical trial to compare outcomes between patients who continued or interrupted OAC during TAVI. The outcomes of interest in this subanalysis were a combination of cardiovascular mortality, stroke, myocardial infarction, major vascular complications or major bleeding at 30 days, stratified by OAC regimen and type, and sex.

Results

After 30 days of follow‐up, 44/296 (14.9%) women reached the combined end point, compared with 90/562 men (16.0%), P =0.732. There were no statistically significant differences between sexes in outcomes, irrespective of the continued or interrupted OAC regimen. Women on vitamin K antagonist had a numerically higher combined event rate (21.7%) compared with women using direct OAC (13.1%), although not statistically significant ( P =0.146), similarly for major vascular complications (15% versus 7.2% in women on vitamin K antagonist and direct OAC respectively [ P =0.255]). The interaction between sex and type of OAC for the combined end point lost significance after correcting for OAC indication and randomization, among others (unadjusted: P =0.037, adjusted=0.090).

Conclusions

After a 30‐day follow‐up of patients undergoing TAVI on OAC, there were no statistically significant differences in outcomes between sexes, independent of interrupted or continued management. Although women treated with vitamin K antagonist had numerically more events than those with direct OAC and an interaction between sex and type of OAC was present, this interaction lost significance after adjustment for other factors. Registration https://clinicaltrials.gov/study/NCT04437303 ; Unique Identifier: NCT044373030.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticoagulantsAortic Valve StenosisStrokeTranscatheter Aortic Valve ReplacementAgedAged, 80 and overFemaleHumansMaleAdministration, OralHemorrhageRisk FactorsSex FactorsTime FactorsTreatment OutcomeVitamin K

Stichwörter der Autor:innen

TAVIbleedingischemic outcomesoral anticoagulantssex differences

Substanzen

AnticoagulantsVitamin K

Autor:innen und Institutionen

  • Department of Cardiology University of Groningen, University Medical Center Groningen the Netherlands.
  • Department of Cardiology St. Antonius Hospital Nieuwegein the Netherlands.
  • Cardiovascular Research Institute Maastricht (CARIM) the Netherlands.

ORCID-Profile: Kees H van Bergeijk, Constantijn S Venema, Hindrik W van der Werf, Ad F M van den Heuvel, Adriaan A Voors, Joanna J Wykrzykowska, Jurrien M Ten Berg

Zitieren

APA

van Bergeijk, K. H., Overduin, D. C., Venema, C. S., van Ginkel, D. J., van der Werf, H. W., van den Heuvel, A. F. M., Voors, A. A., Wykrzykowska, J. J., & Ten Berg, J. M. (2025). Sex Differences in Transcatheter Aortic Valve Implantation Outcomes in Patients on Oral Anticoagulants: A Popular PAUSE TAVI SubAnalysis. Journal of the American Heart Association. https://doi.org/10.1161/jaha.125.043448

Vancouver

van Bergeijk KH, Overduin DC, Venema CS, van Ginkel DJ, van der Werf HW, van den Heuvel AFM, et al. Sex Differences in Transcatheter Aortic Valve Implantation Outcomes in Patients on Oral Anticoagulants: A Popular PAUSE TAVI SubAnalysis. Journal of the American Heart Association. 2025. doi:10.1161/jaha.125.043448

BibTeX
@article{vanBergeijk2025,
  author = {van Bergeijk, Kees H and Overduin, Daniël C and Venema, Constantijn S and van Ginkel, Dirk Jan and van der Werf, Hindrik W and van den Heuvel, Ad F M and Voors, Adriaan A and Wykrzykowska, Joanna J and Ten Berg, Jurrien M},
  title = {Sex Differences in Transcatheter Aortic Valve Implantation Outcomes in Patients on Oral Anticoagulants: A Popular PAUSE TAVI SubAnalysis},
  journal = {Journal of the American Heart Association},
  year = {2025},
  doi = {10.1161/jaha.125.043448}
}
Kostenlos starten →